Candel Therapeutics(CADL.US)

Last Updated 19:00:00 ET
longbridge loading

Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data

benzinga_article·
US
CADL
-3.04%
US
LABU
-2.35%
US
SBIO
-1.24%
benzinga_article·
US
CADL
-3.04%
US
LABU
-2.35%
US
SBIO
-1.24%

Candel Therapeutics Highlights Phase 3 Prostate Cancer Data

Tip Ranks·
US
CADL
-3.04%
US
SBIO
-1.24%
US
XBI
-0.69%
Tip Ranks·
US
CADL
-3.04%
US
SBIO
-1.24%
US
XBI
-0.69%

Candel Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0

Earnings Watch·
US
CADL
-3.04%
Earnings Watch·
US
CADL
-3.04%

Candel Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

Earnings Watch·
US
CADL
-3.04%
Earnings Watch·
US
CADL
-3.04%

Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights | CADL Stock News

StockTitan·
US
CADL
-3.04%
US
BIB
+0.05%
US
PBE
+0.11%
StockTitan·
US
CADL
-3.04%
US
BIB
+0.05%
US
PBE
+0.11%
© 2026 Longbridge｜Disclaimer